Robinson Chandler, the Chief Executive Officer of Monopar Therapeutics, recently reported a transaction involving the acquisition of shares in the company. On October 20, 2026, Chandler acquired 597 shares of common stock at a price of $92.59 per share. This transaction is significant as it underscores the ongoing involvement of company executives in their own firms, particularly in the pharmaceutical preparations sector.
Monopar Therapeutics focuses on developing innovative therapies, and Chandler's recent acquisition reflects his confidence in the company's future. The filing indicates that following this transaction, Chandler now owns a total of 104,127 shares directly.
Background
Monopar Therapeutics, identified by the Central Index Key (CIK) 0001645469, operates in the pharmaceutical preparations industry. The company is incorporated in Delaware and has its fiscal year ending on December 31. Recent filings include multiple Form 4 submissions, indicating ongoing activity among its executives.
What the Filing Says
The SEC filing details that Chandler's acquisition was a direct transaction, coded as 'D' for disposed shares, which were withheld to cover taxes related to the vesting of restricted stock units. The filing states, "Represents additional shares withheld by the issuer to pay for the applicable withholding tax due to administrative error in connection with the vesting and settlement of 12,873 restricted stock units on June 30, 2026..." This highlights the administrative complexities that can arise in stock transactions.
Impact
This transaction may affect stakeholders, including shareholders and potential investors, as it reflects the CEO's financial commitment to Monopar Therapeutics. Additionally, it may influence investor perceptions regarding the company's stability and future growth prospects within the competitive pharmaceutical landscape.
What's Next
The filing does not say what happens next.